Abstract
High activity of dendritic cells (DCs) in inducing cytotoxic T cells (CTLs) led to their application as therapeutic cancer vaccines. The ability of DCs to produce IL-12p70 is one of the key requirements for effective CTL induction and a predictive marker of their therapeutic efficacy in vivo. We have previously reported that defined cocktails of cytokines, involving TNFα and IFNγ, induce mature type-1 polarized DCs (DC1s) which produce strongly elevated levels of IL-12 and CXCL10/IP10 upon CD40 ligation compared to "standard" PGE₂-matured DCs (sDCs; matured with IL-1β, IL-6, TNFα, and PGE₂) and show higher CTL-inducing activity. Guided by our observations that DC1s can be induced by TNFα- and IFNγ-producing CD8⁺ T cells, we have tested the feasibility of using lymphocytes to generate DC1s in a clinically-compatible process, to limit the need for clinical-grade recombinant cytokines and the associated costs. CD3/CD28 activation of bulk lymphocytes expanded them and primed them for effective production of IFNγ and TNFα following restimulation. Restimulated lymphocytes, or their culture supernatants, enhanced the maturation status of immature (i)DCs, elevating their expression of CD80, CD83 and CCR7, and the ability to produce IL-...Continue Reading
References
Jun 1, 1991·Current Opinion in Immunology·R M Steinman, J W Young
Apr 23, 1993·Science·C S HsiehK M Murphy
Aug 1, 1996·The Journal of Experimental Medicine·M CellaG Alber
Feb 17, 1998·European Journal of Immunology·H JonuleitA H Enk
Mar 21, 1998·Nature Medicine·F O NestleD Schadendorf
May 14, 1998·The Journal of Investigative Dermatology·F O NestleG Burg
Jun 3, 2000·Annual Review of Immunology·J BanchereauK Palucka
Jan 4, 2001·Immunological Reviews·F Sallusto, A Lanzavecchia
Feb 24, 2001·The Journal of Experimental Medicine·M V DhodapkarN Bhardwaj
Aug 18, 2001·Cell·A Lanzavecchia, F Sallusto
Feb 21, 2002·The Journal of Experimental Medicine·Robbie B MailliardPawel Kalinski
May 22, 2002·The Journal of Experimental Medicine·Hiroyuki YoneyamaKouji Matsushima
Feb 4, 2003·Nature Reviews. Immunology·Giorgio Trinchieri
Sep 3, 2004·Cancer Research·Robbie B MailliardPawel Kalinski
Dec 21, 2004·Springer Seminars in Immunopathology·Esther C de JongMartien L Kapsenberg
Mar 23, 2005·Biochemical and Biophysical Research Communications·Kojiro SatoHiroko Kanda
Aug 28, 2007·Vaccine·Anja Ten BrinkeS Marieke van Ham
Dec 25, 2007·Journal of Immunotherapy·Lisa H ButterfieldTheresa L Whiteside
Mar 5, 2008·Journal of Immunotherapy·Margherita GiganteElena Ranieri
Apr 23, 2008·Journal of Leukocyte Biology·Je-Jung LeePawel Kalinski
Feb 5, 2009·Cancer Research·Mitsugu FujitaHideho Okada
Mar 5, 2010·European Journal of Immunology·Mirjam R BritschgiSanjiv A Luther
May 26, 2010·Blood·Ravikumar MuthuswamyPawel Kalinski
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Oct 19, 2010·Human Immunology·Christopher PaustianGary K Koski
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hideho OkadaFrank S Lieberman
Dec 15, 2010·Journal of Immunotherapy·Mark A DeBenedetteDon G Healey
Dec 15, 2010·Journal of Immunotherapy·Jessika- M V MüllerLucie M Heinzerling
Apr 6, 2011·Annals of Hematology·Deok-Hwan YangJe-Jung Lee
Citations
May 9, 2014·Cancers·Yuan LinMaie St John
May 4, 2013·Cancer Immunology, Immunotherapy : CII·Xuan WangXiao-Bing Jiang
Mar 17, 2016·Mediators of Inflammation·Tammy OthWilfred T V Germeraad
May 16, 2013·Scandinavian Journal of Immunology·D H Yi, S Appel
Dec 18, 2012·Oncoimmunology·Erik Berk, Pawel Kalinski
Aug 4, 2016·BMC Cancer·David Bernal-EstévezCarlos Parra-López
Apr 26, 2019·Applied Microbiology and Biotechnology·Mariana L PalmaBruno Douradinha
Mar 24, 2021·International Immunopharmacology·Jeong Moo HanEui-Baek Byun